CONGESTIVE HEART FAILURE DRUGS MARKET ANALYSIS

Congestive Heart Failure Drugs MarketSize and Trends

Congestive Heart Failure Drugs Market Drivers:-

Major driver for growth of the congestive heart failure drugs market is the robust pipeline of drugs under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University in collaboration with Scpharmaceuticals Inc. was in phase 2 clinical trials in 2015, this injection is indicated for treatment of heart failure. Furosemide and Azosemide sponsored by Hyogo College of Medicine has completed phase 4 clinical trials in 2016, these drugs are used to treat congestive heart failure. Tolvaptan sponsored by Otsuka pharmaceuticals Co., Ltd was in phase 3 clinical trials in 2016, this drug is indicated for treatment of heart failure in children.

Approval of new drugs from Food and Drug Administration (FDA) is also expected to fuel growth of the congestive heart failure drugs market. In 2016, FDA approved Byvalson by Allergan an Ireland-based company, this drug is used for treatment of hypertension. In 2015, FDA approved Corlanor (ivabradine) by Amgen Inc. a U.S.-based company, this drug treats chronic heart failure. Furthermore, increasing number of geriatric population, unhealthy lifestyle, and increasing awareness regarding treatment of chronic disorders are driving the congestive heart failure drugs market growth.